TC-1 Syngeneic Model Overview
The TC-1 syngeneic model is a widely used murine model of epithelial carcinoma developed on the C57BL/6 background. It was established through transfection of primary mouse lung epithelial cells with the human papillomavirus type 16 (HPV-16) E6 and E7 oncogenes, along with the activated H-ras oncogene. This unique genetic composition makes TC-1 one of the most immunogenic and translationally relevant models for studying virus-associated cancers and for evaluating immunotherapies targeting oncogenic viral antigens.
When implanted subcutaneously or orthotopically into C57BL/6 mice, TC-1 cells form rapidly growing, vascularized tumors that retain strong immunogenicity and reproducible histopathological features. Because of the presence of defined viral antigens, the model is particularly valuable for vaccine development, T-cell epitope mapping, and studies investigating antigen-specific immune memory. TC-1 serves as the standard preclinical system for testing HPV-directed immunotherapies, including peptide vaccines, viral vectors, DNA plasmid vaccines, and immune checkpoint inhibitors targeting virally transformed epithelial tumors.
Request a Custom Quote for TC-1 Syngeneic ModelBiological and Molecular Characteristics
The TC-1 cell line was derived from primary epithelial cells isolated from C57BL/6 mouse lung tissue and transformed with HPV-16 E6 and E7 genes and activated H-ras. These cells exhibit epithelial morphology and express viral oncoproteins that degrade p53 and retinoblastoma (Rb) tumor suppressor proteins, thereby promoting uncontrolled proliferation and transformation. The resulting tumors display histological and immunological features characteristic of virally induced epithelial carcinomas.
The TC-1 model is highly immunogenic due to the continuous expression of HPV-derived E6 and E7 antigens, which elicit strong cytotoxic T-cell responses. The immune microenvironment contains abundant CD8⁺ T cells, macrophages, and dendritic cells, with variable regulatory T-cell infiltration depending on tumor stage. Cytokine expression includes IFN-γ, TNF-α, and IL-2, reflecting active immune engagement. This robust immune responsiveness provides a platform for dissecting mechanisms of immune tolerance, antigen presentation, and vaccine-induced tumor rejection.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Transformed lung epithelial cells (mouse) |
| Genetic background | HPV-16 E6/E7 and activated H-ras |
| Histological type | Poorly differentiated epithelial carcinoma |
| Inoculation route | Subcutaneous, orthotopic, or intravenous |
| Tumor take rate | >95% |
| Doubling time | Approximately 2–3 days in vivo |
| Metastatic potential | Low; primarily localized growth |
| Immunophenotype | Highly immunogenic, strong CD8⁺ T-cell infiltration |
| Common applications | HPV-targeted vaccines, checkpoint inhibitors, T-cell therapy studies |
In Vivo Model Development and Tumorigenicity
TC-1 tumors are typically established by subcutaneous implantation of viable tumor cells into C57BL/6 mice, producing rapidly growing nodules within 4–5 days after inoculation. Orthotopic implantation into relevant mucosal or pulmonary sites provides a physiologically relevant model for studying local immune responses and vaccine efficacy. The model’s consistent tumor take rate and strong immunogenicity enable reliable measurement of therapeutic efficacy and immune activation across experiments.
Because TC-1 expresses viral oncoproteins that are recognized by the immune system, tumor regression can occur in the presence of strong adaptive immune stimulation, such as after vaccination or checkpoint blockade. The model’s defined antigenic landscape allows precise correlation of therapeutic outcome with antigen-specific T-cell responses, cytokine production, and immune memory. These features make TC-1 an ideal platform for testing antigen-targeted immunotherapies, especially those directed against HPV-associated cancers of the cervix, oropharynx, and anogenital tract.
Request a Custom Quote for TC-1 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histologically, TC-1 tumors consist of compact nests of poorly differentiated epithelial cells with high nuclear-to-cytoplasmic ratios and frequent mitotic figures. The tumor parenchyma is surrounded by a fibrous stroma and demonstrates moderate vascularization. Areas of necrosis and immune cell infiltration are commonly observed, reflecting active immune recognition and tumor clearance processes.
Immunohistochemical analysis reveals high Ki-67 expression indicative of rapid proliferation. CD3 and CD8 staining show abundant infiltration of T lymphocytes throughout the tumor mass, consistent with the model’s high immunogenicity. F4/80 and CD11b staining identify macrophages and myeloid cells distributed within the stroma, often in association with T-cell clusters. PD-L1 expression is detectable on both tumor and immune cells and increases in response to interferon signaling. The histopathological characteristics of TC-1 tumors mirror the immune-inflamed phenotype seen in virally driven human cancers, providing a relevant framework for mechanistic immunotherapy research.
Preclinical Applications and Drug Response
The TC-1 syngeneic model is one of the most extensively employed systems for preclinical immunotherapy development, particularly for HPV-driven cancers. It provides a reliable platform for testing therapeutic vaccines targeting HPV E6 and E7 antigens, including DNA vaccines, peptide-based vaccines, viral vectors, and mRNA formulations. Immunization with E6/E7 epitopes elicits potent CD8⁺ T-cell responses that lead to tumor regression and long-term immunologic memory in TC-1–bearing mice.
The model has demonstrated responsiveness to immune checkpoint inhibitors targeting PD-1 and CTLA-4, which enhance T-cell infiltration and antigen-specific cytotoxic activity. Combination therapies integrating vaccination with checkpoint blockade, cytokine agonists (IL-2, IL-12, GM-CSF), or oncolytic viruses further improve tumor control and survival. Due to its defined antigenic landscape, reproducible growth, and immune responsiveness, the TC-1 model remains an essential tool for advancing immunotherapeutic strategies against HPV-related malignancies and other antigen-specific cancer targets.
Request This Model
To request the TC-1 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for TC-1 Syngeneic Model